- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Rathore Wins Thought Leader Award for Biosimilar Characterization
Anurag S. Rathore, PhD, wins a grant and the use of scientific instruments from Agilent to further his investigation.
Anurag S. Rathore, PhD, has become the first from India to receive the Agilent Technologies Thought Leader Award. Rathore was recognized for his contributions to biopharmaceutical research and his efforts to advance the molecular characterization of biosimilars.
The characterization of biosimilars is a process that helps determine the bioequivalence of these products to reference, or original, drugs. Characterization also establishes the nature and extent of differences between biosimilar candidates and their reference products and whether these are clinically meaningful.
As recipient of the award, Rathore receives Agilent equipment and a grant to support his research. He joins 47 others who have received the Agilent awards previously.
Agilent, a 1999 spinoff from Hewlett-Packard, is a Santa Clara, California–based analytical instrumentation developer and manufacturer.
Rathore is a professor and scientist at the Indian Institute of Technology (IIT) Delhi. He earned his PhD from Yale University and currently works in the Department of Chemical Engineering at ITT Delhi. He is a member of the Parenteral Drug Association and American Chemical Society and is the author of more than 400 publications and presentations. He is also editor-in-chief of Preparative Biochemistry and Biotechnology. Information about his publications can be accessed by clicking here.
Rathore recently spoke with The Center for Biosimilars® about a study he conducted on reasons that applications for biosimilar regulatory approval fail.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Eye on Pharma: Interchangeability Labels and Expanded Biosimilar Partnerships
May 29th 2025The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple sclerosis, while 2 other companies expand their biosimilar partnership to include more products.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.
